Neprilysin Inhibitors

Neprilysin inhibitors are a cardiovascular drug class that blocks the neutral endopeptidase enzyme neprilysin, preventing the breakdown of beneficial endogenous vasoactive peptides such as natriuretic peptides, bradykinin, and adrenomedullin In clinical practice, neprilysin inhibition is paired with a renin-angiotensin-aldosterone system blocker—most notably the prodrug sacubitril formulated with valsartan as an angiotensin receptor-neprilysin inhibitor—to offset counterregulatory vasoconstricto...

Neprilysin inhibitors are a cardiovascular drug class that blocks the neutral endopeptidase enzyme neprilysin, preventing the breakdown of beneficial endogenous vasoactive peptides such as natriuretic peptides, bradykinin, and adrenomedullin In clinical practice, neprilysin inhibition is paired with a renin-angiotensin-aldosterone system blocker—most notably the prodrug sacubitril formulated with valsartan as an angiotensin receptor-neprilysin inhibitor—to offset counterregulatory vasoconstricto...

By preserving these peptides, the class promotes vasodilation, natriuresis, diuresis, and antifibrotic cardiovascular signaling

By preserving these peptides, the class promotes vasodilation, natriuresis, diuresis, and antifibrotic cardiovascular signaling In clinical practice, neprilysin inhibition is paired with a renin-angiotensin-aldosterone system blocker—most notably the prodrug sacubitril formulated with valsartan as an angiotensin receptor-neprilysin inhibitor—to offset counterregulatory vasoconstrictor signaling

The class is primarily indicated for the management of chronic heart failure in adults and pediatric patients to decrease the risk of cardiovascular death and hospitalization

The class is primarily indicated for the management of chronic heart failure in adults and pediatric patients to decrease the risk of cardiovascular death and hospitalization